All card news
· Obesity · EU approval
Lose weight with a pill? Lilly's Foundayo gets a thumbs-up in Europe
Europe's expert panel recommended approving Lilly's once-a-day weight-loss pill Foundayo. The European Commission still has the final say.
1 / 7
Show card text
- 1. Lose weight with a pill? Lilly's weight-loss pill Foundayo just got a thumbs-up in Europe Not approved yet: the European Commission has the final say
- 2. What just happened? Fierce Pharma · Oct 16, 2026 Europe's expert panel recommended approving Lilly's once-a-day weight-loss pill, Foundayo. A daily pill for obesity and type 2 diabetes, no needles People lost 5–11% of their weight over 72 weeks (placebo: 2–2.5%) The European Commission still has to sign off
- 3. Weekly shot vs daily pill Most used today A weekly injection Shot Wegovy and Zepbound are self-injected once a week. Foundayo A pill every day Pill Easier to start for people put off by needles.
- 4. Novo got there first, leads nearly 3× 2.9× US weekly prescriptions: Wegovy pill ~173,500 Foundayo ~60,000 HEAD STARTNovo launched 3 months earlier LILLY'S PRICEFrom $149/mo self-pay WEIGHT LOSS5–11% over 72 weeks Source: Fierce Pharma · Oral GLP-1 Tracker (Oct 16, 2026)
- 5. Why it matters beyond the US Patients A needle-free option for Europeonce the Commission signs off Industry The second brand has to catch upon price, access and distribution Careers Launch strategy matters morepricing, market access and supply roles
- 6. 4 things to watch WATCH 01 Final approval Will the Commission follow the panel's advice? WATCH 02 Price What will Foundayo cost in Europe? WATCH 03 The chase Can Lilly catch up with Novo's head start? WATCH 04 Next markets Where does the pill launch next?
- 7. Want news cards like these every week? bio.on_insight BIO:ON Insight | Biotech news, made simple Follow